✓ Medically reviewed✍️ HairBase editorial team📅 Last updated: September 7, 2026⏱ 1 min read
💡 Quick answer
Topical minoxidil (2–5%) is FDA-approved for pattern hair loss in the US. It prolongs the growth phase and boosts scalp blood flow (it is not anti-DHT). Ex
As an AliExpress affiliate, we may earn a commission from qualifying purchases.
Evidence A · Proven
How it is sold where you are
US: 5% topical minoxidil is widely sold OTC; 2% is also marketed. Foam vs liquid differs by brand. Strengths shown here are examples, not a dosing instruction.
Topical minoxidil (2–5%) is FDA-approved for pattern hair loss in the US. It prolongs the growth phase and boosts scalp blood flow (it is not anti-DHT). Expect 3–6 months to first change, continuous use to maintain, and an early "dread shed" that is normal. Strengths shown are labelled examples, not a dosing instruction.
Minoxidil (topical) is one piece — build the whole plan
See how it ranks against every option, tuned to your stage, goal and budget.
1979FDA approves oral minoxidil (Loniten, Upjohn) for severe refractory hypertension; widespread hypertrichosis observed in treated patients becomes the basis for developing a topical hair-loss formulation.
1988FDA approves topical 2% minoxidil solution (Rogaine, Upjohn) as the first drug indicated for male androgenetic alopecia (vertex hair loss).
1991FDA approves topical 2% minoxidil for women with female pattern hair loss, extending the indication beyond men.
1997FDA approves the higher-strength topical 5% minoxidil solution (Extra Strength Rogaine) for men, shown to be more effective than 2%.
2006FDA approves 5% minoxidil foam (a propylene-glycol-free, once- to twice-daily vehicle) for men, improving tolerability; the 5% foam was later approved for women in 2014.
At 48 weeks, 5% topical minoxidil was significantly superior to 2% and placebo in nonvellus hair count and in patient/investigator ratings of scalp coverage; 5% produced ~45% more hair regrowth than 2% and acted earlier, but caused more pruritus and local irritation.
Journal of the American Academy of Dermatology (JAAD) 2002;47(3):377-385
Lucky et al., 20042004
48-week double-blind, placebo-controlled, multicenter RCT; 381 women aged 18-49 with female pattern hair loss (5% n=153, 2% n=154, placebo n=74)
Both 2% and 5% minoxidil were superior to placebo for nonvellus hair count and investigator-assessed regrowth at 48 weeks; 5% was statistically superior to 2% only on the patient-assessed treatment-benefit endpoint, while causing more pruritus, local irritation, and hypertrichosis. Both were well tolerated with no systemic effects.
Journal of the American Academy of Dermatology (JAAD) 2004;50(4):541-553
van Zuuren et al. (Cochrane), 20162016
Systematic review/meta-analysis of 47 RCTs (5,290 participants) on female pattern hair loss; 17 trials evaluated minoxidil
Minoxidil (2% or 5%) roughly doubled the proportion of women achieving at least moderate hair regrowth versus placebo and increased mean total hair count per cm2; 2% and 5% showed no clear difference in efficacy. Adverse events were mild (itch, irritation, off-target hypertrichosis). Evidence was rated low-to-moderate quality.
Cochrane Database of Systematic Reviews 2016, CD007628.pub4
Latest research: The dominant 2023-2026 research direction has shifted toward low-dose oral minoxidil (typically 0.25-5 mg/day) as an alternative or adjunct to topical therapy, driven by adherence and absorption limits of topical formulations; a January 2025 international modified-Delphi consensus (JAMA Dermatology) standardized its off-label use, while studies focus on optimal dosing, combination regimens (e.g., with spironolactone or finasteride), and confirming cardiovascular safety. Topical research is also exploring sulfotransferase-based response prediction and novel vehicles to boost conversion to active minoxidil sulfate.
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
I started minoxidil and now I'm shedding more — did I do something wrong?
A temporary increase in shedding in the first 2–8 weeks (the "dread shed") is common and often reflects follicles resetting their growth cycle. It usually settles within a few weeks, so it's generally not a reason to stop. If the shedding is severe or lasts beyond two months, check in with a dermatologist.
Can women use minoxidil?
Yes — topical minoxidil is FDA-approved for female pattern hair loss as well. Women are often started at a lower concentration, so it's best to confirm the strength and routine with a clinician. If you are pregnant or breastfeeding, talk to your doctor before using it.
How long before I decide it isn't working?
The standard advice is to use it consistently for at least 4–12 months before judging the result. If there's truly no change in that window, ask a clinician to re-check the diagnosis and whether a combination approach would help. Keep in mind that stopping lets any gains fade gradually.
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Figures such as 1 mg or 5% are labelled strengths you may see in your country — not a dosing instruction. Consult a board-certified dermatologist before starting, stopping or changing any treatment.